Hypoglycaemia  ||| S:0 E:14 ||| NNP
and  ||| S:14 E:18 ||| CC
predisposing  ||| S:18 E:31 ||| JJ
factors  ||| S:31 E:39 ||| NNS
among  ||| S:39 E:45 ||| IN
clinical  ||| S:45 E:54 ||| JJ
subgroups  ||| S:54 E:64 ||| NNS
treated  ||| S:64 E:72 ||| VBN
with  ||| S:72 E:77 ||| IN
intensive  ||| S:77 E:87 ||| JJ
insulin  ||| S:87 E:95 ||| NN
therapy  ||| S:95 E:103 ||| NN
In  ||| S:103 E:106 ||| IN
previous  ||| S:106 E:115 ||| JJ
studies ||| S:115 E:122 ||| NNS
,  ||| S:122 E:124 ||| ,
conflicting  ||| S:124 E:136 ||| VBG
intensive  ||| S:136 E:146 ||| JJ
insulin  ||| S:146 E:154 ||| NN
therapy  ||| S:154 E:162 ||| NN
( ||| S:162 E:163 ||| -LRB-
IIT ||| S:163 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
results  ||| S:168 E:176 ||| NNS
have  ||| S:176 E:181 ||| VBP
been  ||| S:181 E:186 ||| VBN
observed ||| S:186 E:194 ||| VBN
,  ||| S:194 E:196 ||| ,
whereby  ||| S:196 E:204 ||| WRB
IIT-related  ||| S:204 E:216 ||| JJ
mortality  ||| S:216 E:226 ||| NN
seems  ||| S:226 E:232 ||| VBZ
to  ||| S:232 E:235 ||| TO
be  ||| S:235 E:238 ||| VB
lower  ||| S:238 E:244 ||| JJR
in  ||| S:244 E:247 ||| IN
specific  ||| S:247 E:256 ||| JJ
clinical  ||| S:256 E:265 ||| JJ
subgroups ||| S:265 E:274 ||| NNS
.  ||| S:274 E:276 ||| .
The  ||| S:276 E:280 ||| DT
aim  ||| S:280 E:284 ||| NN
of  ||| S:284 E:287 ||| IN
this  ||| S:287 E:292 ||| DT
study  ||| S:292 E:298 ||| NN
was  ||| S:298 E:302 ||| VBD
to  ||| S:302 E:305 ||| TO
assess  ||| S:305 E:312 ||| VB
differences  ||| S:312 E:324 ||| NNS
in  ||| S:324 E:327 ||| IN
glycaemic  ||| S:327 E:337 ||| JJ
control ||| S:337 E:344 ||| NN
,  ||| S:344 E:346 ||| ,
the  ||| S:346 E:350 ||| DT
risk  ||| S:350 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
critical  ||| S:358 E:367 ||| JJ
hypoglycaemia  ||| S:367 E:381 ||| NNS
( ||| S:381 E:382 ||| -LRB-
≤  ||| S:382 E:384 ||| FW
2.2  ||| S:384 E:388 ||| FW
mmol ||| S:388 E:392 ||| FW
/ ||| S:392 E:393 ||| FW
l ||| S:393 E:394 ||| FW
) ||| S:394 E:395 ||| -RRB-
,  ||| S:395 E:397 ||| ,
the  ||| S:397 E:401 ||| DT
associated  ||| S:401 E:412 ||| JJ
predisposing  ||| S:412 E:425 ||| JJ
factors ||| S:425 E:432 ||| NNS
,  ||| S:432 E:434 ||| ,
and  ||| S:434 E:438 ||| CC
the  ||| S:438 E:442 ||| DT
in-hospital  ||| S:442 E:454 ||| JJ
mortality  ||| S:454 E:464 ||| NN
in  ||| S:464 E:467 ||| IN
different  ||| S:467 E:477 ||| JJ
clinical  ||| S:477 E:486 ||| JJ
subgroups  ||| S:486 E:496 ||| NNS
treated  ||| S:496 E:504 ||| VBN
with  ||| S:504 E:509 ||| IN
IIT ||| S:509 E:512 ||| NNP
.  ||| S:512 E:514 ||| .
Prospective ||| S:514 E:525 ||| JJ
,  ||| S:525 E:527 ||| ,
observational  ||| S:527 E:541 ||| JJ
study  ||| S:541 E:547 ||| NN
in  ||| S:547 E:550 ||| IN
a  ||| S:550 E:552 ||| DT
university-affiliated  ||| S:552 E:574 ||| JJ
intensive  ||| S:574 E:584 ||| JJ
care  ||| S:584 E:589 ||| NN
unit  ||| S:589 E:594 ||| NN
( ||| S:594 E:595 ||| -LRB-
ICU ||| S:595 E:598 ||| NNP
)  ||| S:598 E:600 ||| -RRB-
conducted  ||| S:600 E:610 ||| VBN
from  ||| S:610 E:615 ||| IN
2004  ||| S:615 E:620 ||| CD
to  ||| S:620 E:623 ||| TO
2005 ||| S:623 E:627 ||| CD
.  ||| S:627 E:629 ||| .
All  ||| S:629 E:633 ||| DT
patients  ||| S:633 E:642 ||| NNS
( ||| S:642 E:643 ||| -LRB-
n  ||| S:643 E:645 ||| CD
=  ||| S:645 E:647 ||| CD
1667 ||| S:647 E:651 ||| CD
)  ||| S:651 E:653 ||| -RRB-
belonging  ||| S:653 E:663 ||| VBG
to  ||| S:663 E:666 ||| TO
one  ||| S:666 E:670 ||| CD
of  ||| S:670 E:673 ||| IN
the  ||| S:673 E:677 ||| DT
six  ||| S:677 E:681 ||| CD
most  ||| S:681 E:686 ||| RBS
common  ||| S:686 E:693 ||| JJ
surgical  ||| S:693 E:702 ||| JJ
intervention  ||| S:702 E:715 ||| NN
groups  ||| S:715 E:722 ||| NNS
( ||| S:722 E:723 ||| -LRB-
cardiac ||| S:723 E:730 ||| JJ
,  ||| S:730 E:732 ||| ,
neuro ||| S:732 E:737 ||| NN
,  ||| S:737 E:739 ||| ,
abdominal ||| S:739 E:748 ||| NN
,  ||| S:748 E:750 ||| ,
vascular ||| S:750 E:758 ||| NN
,  ||| S:758 E:760 ||| ,
orthopaedic ||| S:760 E:771 ||| NN
,  ||| S:771 E:773 ||| ,
and  ||| S:773 E:777 ||| CC
spinal  ||| S:777 E:784 ||| JJ
surgeries ||| S:784 E:793 ||| NN
)  ||| S:793 E:795 ||| -RRB-
and  ||| S:795 E:799 ||| CC
medical  ||| S:799 E:807 ||| JJ
patients  ||| S:807 E:816 ||| NNS
were  ||| S:816 E:821 ||| VBD
included ||| S:821 E:829 ||| VBN
.  ||| S:829 E:831 ||| .
IIT  ||| S:831 E:835 ||| NNP
was  ||| S:835 E:839 ||| VBD
performed  ||| S:839 E:849 ||| VBN
with  ||| S:849 E:854 ||| IN
a  ||| S:854 E:856 ||| DT
target  ||| S:856 E:863 ||| NN
blood  ||| S:863 E:869 ||| NN
glucose  ||| S:869 E:877 ||| NN
level  ||| S:877 E:883 ||| NN
of  ||| S:883 E:886 ||| IN
4.4-7.8  ||| S:886 E:894 ||| CD
mmol ||| S:894 E:898 ||| CD
/ ||| S:898 E:899 ||| CD
l ||| S:899 E:900 ||| NN
.  ||| S:900 E:902 ||| .
Different  ||| S:902 E:912 ||| JJ
indices  ||| S:912 E:920 ||| NNS
were  ||| S:920 E:925 ||| VBD
analysed  ||| S:925 E:934 ||| VBN
to  ||| S:934 E:937 ||| TO
evaluate  ||| S:937 E:946 ||| VB
glucose  ||| S:946 E:954 ||| JJ
control  ||| S:954 E:962 ||| NN
and  ||| S:962 E:966 ||| CC
glycaemic  ||| S:966 E:976 ||| JJ
variability ||| S:976 E:987 ||| NN
.  ||| S:987 E:989 ||| .
The  ||| S:989 E:993 ||| DT
rate  ||| S:993 E:998 ||| NN
of  ||| S:998 E:1001 ||| IN
critical  ||| S:1001 E:1010 ||| JJ
hypoglycaemia  ||| S:1010 E:1024 ||| NN
was  ||| S:1024 E:1028 ||| VBD
significantly  ||| S:1028 E:1042 ||| RB
different  ||| S:1042 E:1052 ||| JJ
within  ||| S:1052 E:1059 ||| IN
the  ||| S:1059 E:1063 ||| DT
different  ||| S:1063 E:1073 ||| JJ
clinical  ||| S:1073 E:1082 ||| JJ
subgroups  ||| S:1082 E:1092 ||| NNS
and  ||| S:1092 E:1096 ||| CC
varied  ||| S:1096 E:1103 ||| VBN
from  ||| S:1103 E:1108 ||| IN
0.8 ||| S:1108 E:1111 ||| CD
%  ||| S:1111 E:1113 ||| NN
to  ||| S:1113 E:1116 ||| TO
4.5 ||| S:1116 E:1119 ||| CD
% ||| S:1119 E:1120 ||| NN
.  ||| S:1120 E:1122 ||| .
Similar  ||| S:1122 E:1130 ||| JJ
results  ||| S:1130 E:1138 ||| NNS
were  ||| S:1138 E:1143 ||| VBD
obtained  ||| S:1143 E:1152 ||| VBN
for  ||| S:1152 E:1156 ||| IN
hyperglycaemia ||| S:1156 E:1170 ||| NN
.  ||| S:1170 E:1172 ||| .
Multivariable  ||| S:1172 E:1186 ||| JJ
analyses  ||| S:1186 E:1195 ||| NNS
for  ||| S:1195 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
predisposing  ||| S:1203 E:1216 ||| JJ
factors  ||| S:1216 E:1224 ||| NNS
of  ||| S:1224 E:1227 ||| IN
critical  ||| S:1227 E:1236 ||| JJ
hypoglycaemia  ||| S:1236 E:1250 ||| NN
showed  ||| S:1250 E:1257 ||| VBD
a  ||| S:1257 E:1259 ||| DT
heterogeneous  ||| S:1259 E:1273 ||| JJ
distribution  ||| S:1273 E:1286 ||| NN
pattern  ||| S:1286 E:1294 ||| NN
among  ||| S:1294 E:1300 ||| IN
the  ||| S:1300 E:1304 ||| DT
different  ||| S:1304 E:1314 ||| JJ
clinical  ||| S:1314 E:1323 ||| JJ
subgroups ||| S:1323 E:1332 ||| NNS
.  ||| S:1332 E:1334 ||| .
Similar  ||| S:1334 E:1342 ||| JJ
results  ||| S:1342 E:1350 ||| NNS
were  ||| S:1350 E:1355 ||| VBD
obtained  ||| S:1355 E:1364 ||| VBN
for  ||| S:1364 E:1368 ||| IN
the  ||| S:1368 E:1372 ||| DT
risk  ||| S:1372 E:1377 ||| NN
factors  ||| S:1377 E:1385 ||| NNS
of  ||| S:1385 E:1388 ||| IN
in-hospital  ||| S:1388 E:1400 ||| JJ
mortality ||| S:1400 E:1409 ||| NN
.  ||| S:1409 E:1411 ||| .
The  ||| S:1411 E:1415 ||| DT
risk  ||| S:1415 E:1420 ||| NN
of  ||| S:1420 E:1423 ||| IN
critical  ||| S:1423 E:1432 ||| JJ
hypoglycaemia  ||| S:1432 E:1446 ||| NN
and  ||| S:1446 E:1450 ||| CC
the  ||| S:1450 E:1454 ||| DT
associated  ||| S:1454 E:1465 ||| JJ
predisposing  ||| S:1465 E:1478 ||| JJ
factors  ||| S:1478 E:1486 ||| NNS
depended  ||| S:1486 E:1495 ||| VBD
on  ||| S:1495 E:1498 ||| IN
the  ||| S:1498 E:1502 ||| DT
clinical  ||| S:1502 E:1511 ||| JJ
subgroup  ||| S:1511 E:1520 ||| NNS
involved ||| S:1520 E:1528 ||| VBN
.  ||| S:1528 E:1530 ||| .
Critical  ||| S:1530 E:1539 ||| JJ
hypoglycaemia  ||| S:1539 E:1553 ||| NN
is  ||| S:1553 E:1556 ||| VBZ
a  ||| S:1556 E:1558 ||| DT
potential  ||| S:1558 E:1568 ||| JJ
threat  ||| S:1568 E:1575 ||| NN
for  ||| S:1575 E:1579 ||| IN
our  ||| S:1579 E:1583 ||| PRP$
patients ||| S:1583 E:1591 ||| NNS
,  ||| S:1591 E:1593 ||| ,
and  ||| S:1593 E:1597 ||| CC
the  ||| S:1597 E:1601 ||| DT
high  ||| S:1601 E:1606 ||| JJ
risk  ||| S:1606 E:1611 ||| NN
of  ||| S:1611 E:1614 ||| IN
critical  ||| S:1614 E:1623 ||| JJ
hypoglycaemia  ||| S:1623 E:1637 ||| NN
in  ||| S:1637 E:1640 ||| IN
some  ||| S:1640 E:1645 ||| DT
clinical  ||| S:1645 E:1654 ||| JJ
subgroups  ||| S:1654 E:1664 ||| NNS
appeared  ||| S:1664 E:1673 ||| VBD
to  ||| S:1673 E:1676 ||| TO
reverse  ||| S:1676 E:1684 ||| VB
the  ||| S:1684 E:1688 ||| DT
benefits  ||| S:1688 E:1697 ||| NNS
of  ||| S:1697 E:1700 ||| IN
IIT ||| S:1700 E:1703 ||| NNP
.  ||| S:1703 E:1705 ||| .
As  ||| S:1705 E:1708 ||| IN
a  ||| S:1708 E:1710 ||| DT
result ||| S:1710 E:1716 ||| NN
,  ||| S:1716 E:1718 ||| ,
it  ||| S:1718 E:1721 ||| PRP
is  ||| S:1721 E:1724 ||| VBZ
crucial  ||| S:1724 E:1732 ||| JJ
that  ||| S:1732 E:1737 ||| IN
the  ||| S:1737 E:1741 ||| DT
different  ||| S:1741 E:1751 ||| JJ
subgroups  ||| S:1751 E:1761 ||| NNS
involved  ||| S:1761 E:1770 ||| VBN
in  ||| S:1770 E:1773 ||| IN
a  ||| S:1773 E:1775 ||| DT
study  ||| S:1775 E:1781 ||| NN
are  ||| S:1781 E:1785 ||| VBP
defined  ||| S:1785 E:1793 ||| VBN
to  ||| S:1793 E:1796 ||| TO
further  ||| S:1796 E:1804 ||| RB
interpret  ||| S:1804 E:1814 ||| VB
the  ||| S:1814 E:1818 ||| DT
potential  ||| S:1818 E:1828 ||| JJ
benefits  ||| S:1828 E:1837 ||| NNS
of  ||| S:1837 E:1840 ||| IN
IIT  ||| S:1840 E:1844 ||| NNP
and  ||| S:1844 E:1848 ||| CC
the  ||| S:1848 E:1852 ||| DT
risk  ||| S:1852 E:1857 ||| NN
of  ||| S:1857 E:1860 ||| IN
critical  ||| S:1860 E:1869 ||| JJ
hypoglycaemia ||| S:1869 E:1882 ||| NN
.  ||| S:1882 E:1884 ||| .
